Scientists discover that the CD74 protein could predict the effectiveness of immunotherapy, advancing colon cancer treatment.

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

With minimal blood loss and scarring, and faster recovery period, robotic surgeries are becoming game changers in the ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel ...

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of ...